Irritable Bowel Syndrome Trial, Recruiting NCT06291038 Sponsor: University Hospital, Rouen Condition: Irritable Bowel Syndrome
Back to Irritable Bowel Syndrome

Irritable Bowel Syndrome Trial, Recruiting

NCT06291038
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are between 18 and 75 years old
  • You have been diagnosed with diarrhea-predominant irritable bowel syndrome (IBS-D), confirmed using a standard set of medical criteria called Rome IV
  • Your IBS symptoms are moderate to severe, based on a specific symptom score (Francis score above 175 out of 500)
  • Any treatments you currently take for IBS have stayed the same for more than 1 month
  • You are covered by a social security/health insurance system
  • You have read, understood, and signed the study consent form
  • If you are a woman who could become pregnant, you have been using a reliable form of contraception (such as the pill, an IUD, or tubal ligation) for at least 1 month, and have a negative pregnancy test
  • If you are a woman who has gone through menopause, this has been confirmed (no periods for at least 12 months without a medical reason, or confirmed by a blood test)

Who may not be able to join:

  • You have taken probiotics, anti-inflammatory medicines, steroids, or antibiotics (by mouth or injection) in the past month or plan to during the study
  • You have a known active autoimmune condition such as type 1 diabetes, lupus, multiple sclerosis, thyroid disease, ankylosing spondylitis, rheumatoid arthritis, or psoriasis
  • You have a known allergy to glutamine
  • You cannot take glutamine, protein powder, lactulose, or mannitol for any medical reason (including an intolerance to sugar-free chewing gum)
  • You have used certain laxatives, lactulose, or protein/glutamine supplements in the 4 weeks before the study starts
  • You have significant kidney problems, liver problems, or a known heart condition
  • You have a history of certain digestive diseases such as coeliac disease, inflammatory bowel disease (e.g. Crohn's or colitis), or abdominal surgery other than appendix or gallbladder removal
  • You have or are suspected of having a blocked or nearly blocked bowel
  • You have or are suspected of having a hole (perforation) in your digestive tract
  • You have abdominal pain whose cause has not been identified
  • You regularly drink more than 14 units of alcohol per week
  • You are pregnant, have recently given birth, or are breastfeeding, or you do not use contraception (for women who could become pregnant)
  • You are under a legal order restricting your freedom, or are under legal guardianship or protective supervision
  • You are currently taking part in another clinical trial, or have done so within the past 2 weeks
  • You have a medical, psychological, or sensory condition that would prevent you from fully understanding what the study involves or from giving informed consent

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
University Hospital, Rouen
Registry
ClinicalTrials.gov
Start date
3 October 2024
Est. completion
1 March 2029

Where this trial is recruiting

🇫🇷 France

Primary endpoints

Evaluate the symptomatic effectiveness of glutamine supplementation in patients suffering from IBS-D with increased intestinal permeability

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov